F. Mornex

10.5k total citations · 2 hit papers
272 papers, 7.0k citations indexed

About

F. Mornex is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, F. Mornex has authored 272 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Pulmonary and Respiratory Medicine, 106 papers in Oncology and 68 papers in Surgery. Recurrent topics in F. Mornex's work include Lung Cancer Diagnosis and Treatment (69 papers), Advanced Radiotherapy Techniques (65 papers) and Lung Cancer Treatments and Mutations (55 papers). F. Mornex is often cited by papers focused on Lung Cancer Diagnosis and Treatment (69 papers), Advanced Radiotherapy Techniques (65 papers) and Lung Cancer Treatments and Mutations (55 papers). F. Mornex collaborates with scholars based in France, United States and Belgium. F. Mornex's co-authors include Nicolas Girard, P. Romestaing, J. Denekamp, O. Chapet, Laurent Bedenne, Jean‐Pierre Gérard, P. Thomas, C. Mariette, M. Bolla and J.J. Pavy and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

F. Mornex

258 papers receiving 6.8k citations

Hit Papers

Phase III trial comparing intensive induction chemoradiot... 2008 2026 2014 2020 2008 2014 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
    2008 501 citations F. Mornex, C. Mariette et al. profile →
  2. Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901
    2014 413 citations C. Mariette, Laëtitia Dahan et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Mornex France 40 3.7k 3.0k 2.5k 1.1k 1.1k 272 7.0k
Edgar Ben‐Josef United States 40 1.9k 0.5× 2.6k 0.9× 2.1k 0.8× 954 0.8× 666 0.6× 159 5.3k
Michael G. Haddock United States 50 4.1k 1.1× 4.1k 1.4× 5.3k 2.1× 555 0.5× 1.1k 1.0× 260 8.9k
Joseph K. Salama United States 45 3.7k 1.0× 2.8k 1.0× 2.5k 1.0× 1.1k 1.0× 366 0.3× 217 7.2k
Alan Horwich United Kingdom 45 5.6k 1.5× 2.6k 0.9× 2.4k 1.0× 1.5k 1.3× 800 0.7× 140 10.4k
Prajnan Das United States 48 3.5k 0.9× 6.0k 2.0× 5.6k 2.2× 1.2k 1.0× 870 0.8× 323 9.8k
Ritsuko Komaki United States 54 7.5k 2.0× 3.1k 1.0× 2.7k 1.1× 2.1k 1.8× 649 0.6× 163 9.3k
Mohammed Mohiuddin United States 51 3.3k 0.9× 5.4k 1.8× 5.3k 2.1× 1.5k 1.3× 472 0.4× 192 9.9k
William T. Sause United States 50 8.3k 2.2× 4.7k 1.6× 2.3k 0.9× 1.8k 1.6× 2.0k 1.8× 173 12.3k
D. Azria France 46 2.8k 0.8× 3.4k 1.1× 2.3k 0.9× 2.0k 1.7× 648 0.6× 372 7.6k
Bhadrasain Vikram United States 40 1.6k 0.4× 2.2k 0.7× 2.3k 0.9× 1.2k 1.1× 435 0.4× 148 5.9k

Countries citing papers authored by F. Mornex

Since Specialization
Citations

This map shows the geographic impact of F. Mornex's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Mornex with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Mornex more than expected).

Fields of papers citing papers by F. Mornex

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Mornex. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Mornex. The network helps show where F. Mornex may publish in the future.

Co-authorship network of co-authors of F. Mornex

This figure shows the co-authorship network connecting the top 25 collaborators of F. Mornex. A scholar is included among the top collaborators of F. Mornex based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Mornex. F. Mornex is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Robb, William B., Julie Véziant, Laëtitia Dahan, et al.. (2025). What are the outcomes for long-term survivors after esophagectomy ? – Evidence from a randomized controlled trial (FFCD9901). European Journal of Surgical Oncology. 51(7). 109736–109736. 1 indexed citations
2.
Khalifa, Jonathan, D. Lerouge, C. Le Péchoux, et al.. (2021). Radiotherapy for primary lung cancer. Cancer/Radiothérapie. 26(1-2). 231–243. 11 indexed citations
3.
Scher, Nathaniel, et al.. (2017). Doses aux organes à risque en radiothérapie conformationnelle et en radiothérapie stéréotaxique : le foie. Cancer/Radiothérapie. 21(6-7). 604–612. 8 indexed citations
4.
Giraud, P., T. Lacornerie, & F. Mornex. (2016). Radiothérapie des cancers primitifs du poumon. Cancer/Radiothérapie. 20. S147–S156. 16 indexed citations
5.
Mariette, C., Laëtitia Dahan, F. Mornex, et al.. (2014). Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901. Journal of Clinical Oncology. 32(23). 2416–2422. 413 indexed citations breakdown →
6.
Thariat, Juliette, Youlia Kirova, G. Milano, & F. Mornex. (2014). Association d’une chimiothérapie ou d’un traitement ciblé à une irradiation stéréotaxique : état des lieux et recommandations préliminaires. Cancer/Radiothérapie. 18(4). 270–279. 15 indexed citations
7.
Robb, William B., Laëtitia Dahan, F. Mornex, et al.. (2014). Impact of Neoadjuvant Chemoradiation on Lymph Node Status in Esophageal Cancer. Annals of Surgery. 261(5). 902–908. 61 indexed citations
8.
9.
Antoni, D., Hélène Burckel, Elodie Josset, G. Noël, & F. Mornex. (2014). Radiobiologie des doses ablatives en radiothérapie stéréotaxique : mise au point des données récentes. Cancer/Radiothérapie. 18(4). 264–269. 5 indexed citations
10.
Houtte, P. Van, Martine Roelandts, & F. Mornex. (2011). Radiothérapie des cancers bronchiques : place de l’irradiation médiastinale prophylactique en 2011. Cancer/Radiothérapie. 15(6-7). 509–513. 6 indexed citations
11.
Girard, Nicolas & F. Mornex. (2010). Highlights of the 2nd European Lung Cancer Conference. Expert Review of Anticancer Therapy. 10(7). 1023–1025. 1 indexed citations
12.
Girard, Nicolas & F. Mornex. (2005). Place de la chimioradiothérapie concomitante dans le traitement des cancers bronchiques. Bulletin du Cancer. 92(12). 1048–1064. 5 indexed citations
13.
Chapet, O., P. Romestaing, F. Mornex, et al.. (2005). Preoperative radiotherapy for rectal adenocarcinoma: Which are strong prognostic factors?. International Journal of Radiation Oncology*Biology*Physics. 61(5). 1371–1377. 40 indexed citations
14.
Mornex, F., et al.. (2004). [Chemoradiation for pancreatic adenocarcinoma].. PubMed. 8 Suppl 1. S80–7. 2 indexed citations
15.
Eberhardt, Wilfried, Kathy S. Albain, Harvey I. Pass, et al.. (2003). Induction treatment before surgery for non-small cell lung cancer. Lung Cancer. 42(2). 9–14. 44 indexed citations
16.
Bourhis, Jean & F. Mornex. (1998). Bases biologiques de la chimioradiothérapie. Cancer/Radiothérapie. 2(6). 657–662. 6 indexed citations
17.
Ginsberg, Robert J., James D. Cox, H. Bülzebruck, et al.. (1997). Staging classification committee. Lung Cancer. 17. S11–S13. 15 indexed citations
18.
Cowen, D., Pierre Richaud, F. Mornex, et al.. (1995). Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. Radiotherapy and Oncology. 34(1). 9–16. 107 indexed citations
19.
Mornex, F., S. Bertrand, Daniel Devriendt, et al.. (1994). Bases biologiques de la radiorésistance des astrocytomes de haut grade de malignité.. 81(4). 342–350. 2 indexed citations
20.
Patronas, N J, Jack S. Cohen, Richard H. Knop, et al.. (1986). Metalloporphyrin contrast agents for magnetic resonance imaging of human tumors in mice.. PubMed. 70(3). 391–5. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edgar Ben‐Josef Breakdown of academic impact, for papers by Michael G. Haddock Breakdown of academic impact, for papers by Joseph K. Salama Breakdown of academic impact, for papers by Alan Horwich Breakdown of academic impact, for papers by Prajnan Das Breakdown of academic impact, for papers by Ritsuko Komaki Breakdown of academic impact, for papers by Mohammed Mohiuddin Breakdown of academic impact, for papers by William T. Sause Breakdown of academic impact, for papers by D. Azria Breakdown of academic impact, for papers by Bhadrasain Vikram
Rankless by CCL
2026